Skip to main content
Fig. 7 | Stem Cell Research & Therapy

Fig. 7

From: Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer

Fig. 7

a Box plots of the estimated IC50 values of several chemotherapy drugs between high and low stemness-risk groups. Wilcoxon test, ns, not significance; ***p < 0.001. b TIDE results of the differences of stemness-risk score in the respond and non-respond groups and distributions of responder and non-responder in distinct stemness-risk groups. c Differences of stemness-risk score in SD/PD and CR/PR groups and distributions of anti-PD-L1 therapeutic response in distinct stemness-risk groups in IMvigor210 cohort. d Kaplan–Meier survival analysis revealed high stemness-risk score correlated with a worse prognosis in IMvigor210 cohort. e Differences of stemness-risk score in PD and CR/PR groups and distributions of anti-PD-1 therapeutic response in distinct stemness-risk groups in GSE78220 cohort

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512